| Year |
Citation |
Score |
| 2023 |
Kuser-Abali G, Zhang Y, Szeto P, Zhao P, Masoumi-Moghaddam S, Fedele CG, Leece I, Huang C, Cheung JG, Ameratunga M, Noguchi F, Andrews MC, Wong NC, Schittenhelm RB, Shackleton M. UHRF1/UBE2L6/UBR4-mediated ubiquitination regulates EZH2 abundance and thereby melanocytic differentiation phenotypes in melanoma. Oncogene. PMID 36906655 DOI: 10.1038/s41388-023-02631-8 |
0.67 |
|
| 2021 |
Vergara IA, Mintoff CP, Sandhu S, McIntosh L, Young RJ, Wong SQ, Colebatch A, Cameron DL, Kwon JL, Wolfe R, Peng A, Ellul J, Dou X, Fedele C, Boyle S, et al. Evolution of late-stage metastatic melanoma is dominated by aneuploidy and whole genome doubling. Nature Communications. 12: 1434. PMID 33664264 DOI: 10.1038/s41467-021-21576-8 |
0.674 |
|
| 2017 |
Noguchi F, Inui S, Fedele C, Shackleton M, Itami S. Calcium-Dependent Enhancement by Extracellular Acidity of the Cytotoxicity of Mitochondrial Inhibitors against Melanoma. Molecular Cancer Therapeutics. 16: 936-947. PMID 28223427 DOI: 10.1158/1535-7163.Mct-15-0235 |
0.653 |
|
| 2016 |
Paul PJ, Raghu D, Chan AL, Gulati T, Lambeth L, Takano E, Herold MJ, Hagekyriakou J, Vessella RL, Fedele C, Shackleton M, Williams ED, Fox S, Williams S, Haupt S, et al. Restoration of tumor suppression in prostate cancer by targeting the E3 ligase E6AP. Oncogene. PMID 27641331 DOI: 10.1038/Onc.2016.159 |
0.64 |
|
| 2016 |
Alsop K, Thorne H, Sandhu S, Hamilton A, Mintoff C, Christie E, Spruyt O, Williams S, McNally O, Mileshkin L, Ananda S, Hallo J, Loi S, Scott C, Savas P, ... ... Fedele C, et al. A community-based model of rapid autopsy in end-stage cancer patients. Nature Biotechnology. PMID 27617737 DOI: 10.1038/Nbt.3674 |
0.653 |
|
| 2016 |
Tan LY, Mintoff C, Johan MZ, Ebert BW, Fedele C, Zhang YF, Szeto P, Sheppard KE, McArthur GA, Foster-Smith E, Ruszkiewicz A, Brown MP, Bonder CS, Shackleton M, Ebert LM. Desmoglein 2 promotes vasculogenic mimicry in melanoma and is associated with poor clinical outcome. Oncotarget. PMID 27340778 DOI: 10.18632/Oncotarget.10216 |
0.647 |
|
| 2016 |
Boyle SE, Fedele CG, Corbin V, Wybacz E, Szeto P, Lewin J, Young RJ, Wong A, Fuller R, Spillane J, Speakman D, Donahoe S, Pohl M, Gyorki D, Henderson MA, et al. CD271 Expression on Patient Melanoma Cells Is Unstable and Unlinked to Tumorigenicity. Cancer Research. PMID 27325642 DOI: 10.1158/0008-5472.Can-15-2377 |
0.674 |
|
| 2014 |
Fedele C, Tothill RW, McArthur GA. Navigating the challenge of tumor heterogeneity in cancer therapy. Cancer Discovery. 4: 146-8. PMID 24501303 DOI: 10.1158/2159-8290.Cd-13-1042 |
0.394 |
|
| 2012 |
Gembarska A, Luciani F, Fedele C, Russell EA, Dewaele M, Villar S, Zwolinska A, Haupt S, de Lange J, Yip D, Goydos J, Haigh JJ, Haupt Y, Larue L, Jochemsen A, et al. MDM4 is a key therapeutic target in cutaneous melanoma. Nature Medicine. 18: 1239-47. PMID 22820643 DOI: 10.1038/Nm.2863 |
0.645 |
|
| Show low-probability matches. |